Green Cross to seek re-approval over human placenta injection

Published: 2009-03-31 06:59:00

Updated: 2009-03-31 06:59:00

Green Cross Corporation said on March 26 that it will proceed to re-apply for its Greenpla, which was judged by the Korea Food and Drug Administration to be ineffective for treatment of climacteric disturbance.

According to the company, the product’s dosage administration will be changed from ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK